Skip to main content
. 2017 Oct;72(10):588–594. doi: 10.6061/clinics/2017(10)01

Figure 2.

Figure 2

A = Progression-free survival for patients with targeted therapy against HER2 versus any other targeted therapy. B = Overall survival for patients with targeted therapy against HER2 versus any other targeted therapy.